Oral equivalent to unasyn

Acute bacterial sinusitis may be the complication of an initial viral illness. The primary bacterial isolates are S. aureus, S. pneumoniae, Haemophilus influenzae , and Moraxella catarrhalis . 9 The . Food and Drug Administration (FDA) has labeled gatifloxacin, moxifloxacin, sparfloxacin, and levofloxacin for use in the treatment of acute bacterial sinusitis. Clinical trials comparing fluoroquinolones with amoxicillin-clavulanate potassium (Augmentin), cefuroxime axetil (Ceftin), and clarithromycin (Biaxin) have demonstrated the efficacy of the quinolone antibiotics. 9 However, we believe that quinolones should not be used as first-line agents in the treatment of acute bacterial sinusitis because of the potential for development of bacterial resistance.

The incidence of diarrhea a was significantly lower in patients in the every 12 hours treatment group compared to patients who received the every 8 hours regimen (% and %, respectively). In addition, the number of patients with either severe diarrhea or who were withdrawn with diarrhea was significantly lower in the every 12 hours treatment group (% and % for the every 12 hours/10 day and every 8 hours/10 day, respectively). In the every 12 hours treatment group, 3 patients (%) were withdrawn with an allergic reaction, while 1 patient (%) in the every 8 hours group was withdrawn for this reason. The number of patients with a candidal infection of the diaper area was % and % for the every 12 hours and every 8 hours groups, respectively.

Data from a controlled clinical trial conducted in pediatric patients provided evidence supporting the safety and efficacy of UNASYN for the treatment of skin and skin structure infections. Of 99 pediatric patients evaluable for clinical efficacy, 60 patients received a regimen containing intravenous UNASYN, and 39 patients received a regimen containing intravenous cefuroxime . This trial demonstrated similar outcomes (assessed at an appropriate interval after discontinuation of all antimicrobial therapy) for UNASYN- and cefuroxime-treated patients:

Oral equivalent to unasyn

oral equivalent to unasyn